Navigation Links
Clarient Reports 2009 Third Quarter; Nine Month Results
Date:11/3/2009

--- --- ------ --- Net loss applicable to common stockholders $(3,235) $(2,214) $(7,652) $(7,427) ======= ======= ======= ======= Net income (loss) per share applicable to common stockholders- basic and diluted: Loss from continuing operations $(0.04) $(0.03) $(0.11) $(0.10) Income from discontinued operations - - 0.01 - --- --- ---- --- Net loss applicable to Common stockholders $(0.04) $(0.03) $(0.10) $(0.10) ====== ====== ====== ====== Weighted-average number of common shares outstanding - basic and diluted: 77,582,829 75,842,169 77,256,895 74,307,956 


                                 Clarient, Inc.
          Reconciliation of Loss from Continuing Operations to "Adjusted
                                      EBITDA"

                                 Three months ended       Nine months ended
                                    September 30,            September 30,
                                  2009      2008(*)       2009        2008(*)
                                  ----       ------       ----        ------
    Loss from Continuing
     Operations, before income
     taxes                     $(3,235)    $(2,214)    $(4,862)      $(7,421)
    Income tax expense
     (benefit)                       -           -        (599)            6
    Interest Expense, net          144       2,399       4,056         5,747
    Depreciation &
     Amortization                1,039         961       2,820         2,815
    Stock Compensation Expense     501         241       1,640         1,424
                                  
'/>"/>
SOURCE  Clarient, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 

Related biology technology :

1. Clarient to Present at Noble Financials 5th Annual Equity Conference on Tuesday, June 9th
2. Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners
3. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
4. Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008
5. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
6. Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer
7. Jim Agnello to Resign as Clarient Chief Financial Officer
8. Clarient Announces Fourth Quarter and Year-End 2007 Financial Results
9. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
10. Clarient to Commercialize Novel Breast Cancer Profile
11. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...Y and BLENHEIM, Ontario, Nov. 24 /PRNewswire-First...t is acquiring the assets of Hyland Seeds, a divis... addition of Hyland Seeds will further expand Dow ...y anticipates the introduction of SmartStax(TM) ...t Trait Technology in corn in 2012. The transactio...
(Date:11/24/2009)... LOUIS, Nov. 24 Sigma-Al...ing at the NASDAQ OMX conference on Tuesday, Decem...Interested parties may listen via live audio broad... s tor.sig m a a ldrich.com/ . Users can cl..., About Sigma-Aldrich: Sigma-Aldrich is a lead...
(Date:11/24/2009)... , REYKJAVIK, Iceland, November 24 /PRNews...DCGN ) today announced the approval of all of its,...or the District of Delaware,(the "Bankruptcy Court...r,relief under Chapter 11 of the United States Ban... The orders issued by the Bankruptcy Court allow t...
(Date:11/24/2009)...N MATEO, Calif., Nov. 24 ...ical company focused on developing and commerciali...day that Anthony DiTonno, President and Chief Exec... Annual Piper Jaffray Health Care Conference, to b...otel in New York, New York. ,, Mr. DiTonno and...
Breaking Biology Technology:Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 3deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3
... 4 Rochester Medical,Corporation (Nasdaq: ROCM )...uarter ending December 31, 2007., The Company rep...compared to $7,512,000 for the first quarter of la...r $.02 per diluted share compared to a net income,...first quarter of last,year. Net income for the fir...
...rst to be Awarded Shingo Prize Outside of North ...Ill., Feb. 4 Baxter International Inc.,s,(NYSE: ...a has been,recognized with the 2008 Shingo Prize f...st to be awarded the Shingo Prize outside North Am...driving higher quality and,improvements in product...
...eth (NYSE: WYE ),announced today that it will pre...al, Biotechnology and Medical Device Conference on...ime. Presenting for Wyeth will be,Geno Germano, Pr...e, Wyeth,Pharmaceuticals., Wyeth,s presentation w...yeth.com and available for replay following the c...
Other Biology Technology:Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter 2Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter 3Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter 4Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter 5Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter 6Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter 7Baxter's Costa Rica Facility Recognized With Shingo Prize for Excellence in Manufacturing 2Wyeth to Present at the Merrill Lynch 2008 Global Pharmaceutical, Biotechnology and Medical Device Conference 2
(Date:11/25/2009)...rs and ambulance workers faced a terrifying rescue...ttled to save people from the collapsing Twin Towe...uated as many people as they could in an area whic... their jobs even harder was the problem of poor co...es jammed mobile networks with calls and the emerg...
(Date:11/25/2009)...ps some 250 million liters of blood through the bo...the heart have to be extremely durable. The resear...air of the Department of Medicine III at Heidelber...atus), has discovered a protein that is responsibl... the sarcomere. In cooperation with other research...
(Date:11/24/2009)...d by traditional healers in Brazil to treat a rang...ever and flu. , Now for the first time, researche...tifically prove the pain relieving properties of .... , Testing this ancient South American herb on m... able to show that when prepared as a ,tea, the t...
Breaking Biology News(10 mins):Magic box for mission impossible 2Magic box for mission impossible 3New genetic cause of cardiac failure discovered 2Got a pain? -- Have a cup of Brazilian mint 2Neuro Kinetics 26amp 3B Military Researchers in Push To Improve Diagnosis 26amp 3B Treatment of Combat Brain Injuries 5842 1Neuro Kinetics 26amp 3B Military Researchers in Push To Improve Diagnosis 26amp 3B Treatment of Combat Brain Injuries 5842 2Tamaulipas Comparative Wound Healing Test Treatment Successfully Concluded 5839 1Tamaulipas Comparative Wound Healing Test Treatment Successfully Concluded 5839 2Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 5836 1Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 5836 2Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 5836 3Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 5836 4Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 5836 5Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 5836 6Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 5836 7Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 5836 8Shire to Present Important Study Findings on its ADHD Treatments at a Major Psychiatric Meeting on October 29 and 30 5836 9
...shade trees may improve crops, resistance to tempe...nges are expected to trigger, according to an arti.... The article, by Brenda B. Lin, Ivette Perfecto, ..., focuses on coffee production, although their con... important crops, including cocoa and tea, which a...
...Biometric Access Control Solution, ...., Sept. 30 BIO-key International,Inc. (OTC Bulle...ty,solutions and finger-based biometric identifica...nte"), a leading accounting and consultant firm, h...to secure their new,headquarters., Parente, headq...
...American Scientists (FAS) will reach new levels wi...te immunology video game through a generous grant ...d fun game is available for download at http://fa...next version of Immune Attack in February 2009," s...earning Technologies Program. "We,re interested i...
Other Biology News:Parente Randolph Secures Access to New Corporate Headquarters With BIO-key(R) Biometric Identification 2Parente Randolph Secures Access to New Corporate Headquarters With BIO-key(R) Biometric Identification 3Entertainment Software Association Foundation awards grant to FAS for immune attack 2
UCB CD4 T Cell Chip-IHC from 3H Biomedical AB
NK Cell Chip-IHC from 3H Biomedical AB
Yeast tRNA 50 l from BD Biosciences Pharmingen
UCB Neutrophil Chip-IHC from 3H Biomedical AB
Biology Products: